2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Christopher R. D’Angelo, MD, discusses novel therapeutics under investigation in patients with diffuse large B-cell lymphoma.
Christopher R. D’Angelo, MD, an assistant professor in the Department of Internal Medicine, Division of Hematology/Oncology at the University of Nebraska Medical Center, discusses novel therapeutics under investigation in patients with diffuse large B-cell lymphoma (DLBCL).
Emerging bispecific T-cell engager therapies are showing promise within the relapsed/refractory setting, says D'Angelo. Next-generation BTK inhibitors have also been shown to induce responses in patients who have progressed following treatment with ibrutinib (Imbruvica), D’Angelo adds. Moreover, it has been suggested that resistance mechanisms may potentially be overcome with some of these effective, novel therapies, D'Angelo concludes.